In a study characterizing the therapeutic potential of miR-7-AAVs and S-TRAIL-MSCs for glioblastomas, the delivery of miR-7 via AAV led to upregulation of death receptor5 (DR 5), also known as TRAIL. Here, TNFSF10 is linked to glioblastoma.